Lipoxin A4 Attenuates Bronchopulmonary Dysplasia via Upregulation of Let-7c and Downregulation of TGF-β1 Signaling Pathway

Inflammation. 2017 Dec;40(6):2094-2108. doi: 10.1007/s10753-017-0649-7.

Abstract

Transforming growth factor-β (TGF-β) superfamily members are key regulators for lung development and progress of bronchopulmonary dysplasia (BPD). The mechanisms by which lipoxin A4 (LXA4) attenuates development of BPD have not been clarified. Neonatal murine BPD models were inducted by hyperoxia treatment. Neonatal mice were exposed to room air or 85% O2 hyperoxia with or without treatment with 5S,6R-methyl-LXA4 or anti-TGF-β antibodies. Mouse lung epithelial cells (MLE-12 cells) and mouse embryonic fibroblasts (NIH/3T3 cells) were cultured in room air or 85% O2 followed by treatment of LXA4, anti-TGF-β antibodies, and let-7c mimic/anti-microRNA transfections. Treatment with 5S,6R-methyl-LXA4 and anti-TGF-β antibodies both attenuated the mice alveolar simplification induced by hyperoxia. Hyperoxia treatment significantly altered pulmonary basal mRNA and protein expressions of several important extracellular matrix (ECM) and ECM remodeling proteins including fibronectin, α-smooth muscle actin (α-SMA), tissue inhibitor of metalloproteinase-1 (TIMP-1), elastin, tenascin C, collagen I, and matrix metalloproteinase-1 (MMP-1). 5S,6R-methyl-LXA4 and anti-TGF-β antibodies suppressed the mRNA and protein expressions of TGF-β1 and TGF-βR1 but not TGF-βR2 in the lungs exposed to hyperoxia. Treatment with LXA4 and anti-TGF-β antibodies alleviated hyperoxia-induced injury of the NIH/3T3 cells identified by morphologic observation and flow cytometry, and expressions of ECM, ECM remodeling proteins, and TGF-β1 signaling pathway, but reversed by transfection with let-7c anti-miRNA. LXA4 upregulated the let-7c expression in MLE-12 cells, transfection with let-7c anti-miRNA, inhibited the LXA4-induced let-7c expression in MLE-12 cells exposed to hyperoxia and reduced the relative luciferase activity of let-7c binding with let-7c binding sites of the TGF-βR1 3' UTR. Treatment with 5S,6R-methyl-LXA4 and anti-TGF-β antibodies significantly improved histology, ECM, and ECM remodeling proteins in the lungs isolated from the murine BPD model induced by hyperoxia. The LXA4-imparted protective effects on hyperoxia-induced lung injury are mediated by upregulation of let-7c and inhibition of TGF-β1 and subsequent downregulation of TGF-β1 signaling pathway.

Keywords: bronchopulmonary dysplasia; let-7; lipoxin A4; transforming growth factor-β.

MeSH terms

  • Animals
  • Animals, Newborn
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Bronchopulmonary Dysplasia / drug therapy
  • Bronchopulmonary Dysplasia / prevention & control*
  • Down-Regulation / drug effects
  • Lipoxins / pharmacology*
  • Mice
  • MicroRNAs / metabolism*
  • NIH 3T3 Cells
  • Signal Transduction / drug effects*
  • Transforming Growth Factor beta1 / metabolism*
  • Up-Regulation

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Lipoxins
  • MicroRNAs
  • Transforming Growth Factor beta1
  • lipoxin A4
  • mirnlet7 microRNA, mouse